JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hendershot, L. C.
Right arrow Articles by Chenoweth, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hendershot, L. C.
Right arrow Articles by Chenoweth, M. B.
Journal of Pharmacology And Experimental Therapeutics, Vol. 110, Issue 3, 344-351, 1954
Copyright © 1954 by American Society for Pharmacology and Experimental Therapeutics

ANTAGONISM OF THREE HOMOLOGOUS MONOFLUORINATED FATTY ACIDS BY SEVERAL FATTY ACIDS

Leland C. Hendershot 1 and Maynard B. Chenoweth 2

1 Departnwnt of Pharmacology, University of Michigan, Ann Arbor
2 The Dow Chemical Company, Midland, Michigan

1. In the presence of either acetate, butyrate, or hexanoate as substrates, fluoroacetate, fluorobutyrate, and fluorohexanoate all inhibit the isolated rabbit intestinal strip; but the various substrates antagonize the fluoroacids to different degrees.

2. Fluoroacetate is best antagonized by acetate; fluorobutyrate and fluorohexanoate are best antagonized by hexanoate.

3. The effects of the fluoro fatty acids upon fatty acid metabolism and its possible significance in fluoroacid poisoning is discussed in the light of specific fatty acid enzyme systems.

Submitted on November 12, 1953






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1954 by the American Society for Pharmacology and Experimental Therapeutics.